Exelixis (EXEL) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Cowen Upgrades Exelixis (EXEL) to Outperform
November 5, 2014 6:58 AM ESTCowen upgraded Exelixis (NASDAQ: EXEL) from Market Perform to Outperform.
For an analyst ratings summary and ratings history on Exelixis click here. For more ratings news on Exelixis click here.
Shares of Exelixis closed at $1.65 yesterday.
... MoreExelixis, Inc. (EXEL) Reports Top-Line Results From a Phase 2 Trial of Cabozantinib
November 4, 2014 4:21 PM ESTExelixis, Inc. (NASDAQ: EXEL) today announced positive top-line results from a randomized phase 2 trial of cabozantinib and erlotinib alone or in combination as second- or third-line therapy in patients with stage IV EGFR wild-type non-small cell lung cancer (NSCLC). This trial (Study E1512) is sponsored by the U.S. National Cancer Institute (NCI) through a Cooperative Research and Development Agreement between the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis, NCI and Exelixis. Study E1512 was designed and is being conducted by the ECOG-ACRIN Cancer Research Group as part of Exelixis... More
